PMID- 9193360
OWN - NLM
STAT- MEDLINE
DCOM- 19970710
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 15
IP  - 4
DP  - 1997 Apr
TI  - Hematopoietic recovery after allogeneic blood stem-cell transplantation compared 
      with bone marrow transplantation in patients with hematologic malignancies.
PG  - 1608-16
AB  - PURPOSE: To compare hematopoietic recovery, duration of hospitalization, and 
      100-day survival in patients who received allogeneic-blood stem cells (BSC) or 
      conventional allogeneic bone marrow transplantation (BMT). PATIENTS AND METHODS: 
      From December 1994 to August 1995, 21 patients participated in a phase II study 
      of allogeneic BSC transplantation. Cells mobilized with granulocyte 
      colony-stimulating factor (G-CSF; 5 micrograms/kg/ d) were collected from human 
      leukocyte antigen (HLA)-matched related donors and cryopreserved. 
      Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and 
      methotrexate. G-CSF (10 micrograms/kg/d) was administered posttransplant. The 
      outcomes were compared with 22 identically treated historical patients who 
      received allogeneic BMT. RESULTS: The median infused CD34+ cell and 
      granulocyte-macrophage colony-forming unit (CFU-GM) content were 7.73 x 10(4)/kg 
      and 41.6 x 10(4)/kg, respectively. The median time to a neutrophil count greater 
      than 500/ microL was 11 days after BSC and 16.5 days after BMT (P = .0003). A 
      trend toward faster platelet and RBC recovery after BSC was observed. BSC 
      patients received fewer platelet transfusions: 10 versus 19 (P = .015). The 
      median length of hospitalization was shorter after BSC transplantation: 25 versus 
      31.5 days (P = .0243). The 100-day survival rates were similar: 83% after BSC and 
      75% after BMT (P = .3585). The incidence of acute GVHD grade II to IV was 57% and 
      45% for BSC and BMT, respectively (P = .4654). CONCLUSION: In comparison to BMT, 
      allogeneic BSC transplantation may result in faster hematopoietic recovery, 
      shorter hospital stay, and similar early survival. Whether allogeneic BSC are 
      superior to bone marrow needs to be determined in randomized trials.
FAU - Pavletic, Z S
AU  - Pavletic ZS
AD  - Department of Internal Medicine, University of Nebraska Medical Center, Omaha 
      68198-3330, USA.
FAU - Bishop, M R
AU  - Bishop MR
FAU - Tarantolo, S R
AU  - Tarantolo SR
FAU - Martin-Algarra, S
AU  - Martin-Algarra S
FAU - Bierman, P J
AU  - Bierman PJ
FAU - Vose, J M
AU  - Vose JM
FAU - Reed, E C
AU  - Reed EC
FAU - Gross, T G
AU  - Gross TG
FAU - Kollath, J
AU  - Kollath J
FAU - Nasrati, K
AU  - Nasrati K
FAU - Jackson, J D
AU  - Jackson JD
FAU - Armitage, J O
AU  - Armitage JO
FAU - Kessinger, A
AU  - Kessinger A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - Adult
MH  - *Bone Marrow Transplantation
MH  - Female
MH  - Granulocyte Colony-Stimulating Factor
MH  - Hematologic Neoplasms/*physiopathology/*surgery
MH  - *Hematopoiesis
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Survival Analysis
MH  - Tissue Donors
MH  - Transplantation, Homologous
MH  - Treatment Outcome
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
AID - 10.1200/JCO.1997.15.4.1608 [doi]
PST - ppublish
SO  - J Clin Oncol. 1997 Apr;15(4):1608-16. doi: 10.1200/JCO.1997.15.4.1608.